Work

CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma—Kinase Inhibition Redux

Year: 2015

Type: editorial

Abstract: In the January 15, 2012, issue of Clinical Cancer Research, Kirkwood and colleagues published a study comparing the MEK inhibitor selumetinib with temozolomide in unselected metastatic melanoma. Although selumetinib did not improve survival or response, most responders had BRAF-activating mutations, and selumetinib has since demonstrated efficacy in BRAF-mutant melanoma. This study laid the groundwork for the evaluation of BRAF/MEK inhibitors in BRAF-mutant melanoma. Clin Cancer Res; 21(24); 5412–4. ©2015 AACR. See related article by Kirkwood et al., Clin Cancer Res 2011;18(2) January 15, 2012;555–67

Source: Clinical Cancer Research

DOI: 10.1158/1078-0432.ccr-14-3132

Authors: Diwakar Davar, John M. Kirkwood

Institution: University of Pittsburgh Medical Center

Language: English

Topic: Melanoma and MAPK Pathways

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: green

Funder: National Cancer Institute